Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

ense. 

Total operating costs and expenses in the second quarter of 2014 were $51.4 million as compared to $66.5 million in the second quarter of 2013.  Total operating costs and expenses in the first half of 2014 were $107.6 million as compared to $134.6 million in the first half of 2013.  Total operating costs and expenses decreased primarily as a result of decreased research and development (R&D) expense, as well as decreased cost of goods sold associated with decreased manufacturing activity.

Research and development expense in the second quarter of 2014 was $36.7 million as compared to $52.2 million in the second quarter of 2013.  For the first half of 2014, R&D expense was $75.0 million as compared to $97.8 million in the first half of 2013.  R&D expense was lower in the second quarter and first half of 2014 as compared to the same periods in 2013 primarily because of reduced expenses for the Phase 3 study of etirinotecan pegol (NKTR-102) in metastatic breast cancer, which completed enrollment in the third quarter of 2013. Additionally, R&D expense in the second quarter and first half of 2013 included costs related to the Phase 2 study of NKTR-181, which was completed in 2013.  These decreases in R&D expense in 2014 were partially offset by costs for the preparation for the start of Phase 3 for NKTR-181, the ongoing Phase 1 study of NKTR-171, and the continued production of devices for the ongoing Phase 3 studies of Amikacin Inhale.

General and administrative expense was $9.6 million in the second quarter of 2014 as compared to $9.2 million in the second quarter of 2013.  G&A expense in the first half of 2014 was $19.5 million as compared to $20.1 million in the first half of 2013.

Non-cash interest expense incurred in connection with the 2012 royalty monetization was $5.1 million and $10.5 million in the second quarter and first half of 2014, respectively, as compared to $
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... -- Compass Diversified Holdings (NYSE: CODI ) ("CODI," ... middle market businesses, announced today its consolidated operating results ... 2014. Fourth Quarter 2014 Highlights , ... or "Cash Flow") of $17.5 million for the fourth ... year 2014;  , Reported net income of $8.9 ...
(Date:3/2/2015)... , March 2, 2015  DURECT Corporation ... Epigenomic Regulator Program, and the successful completion of ... lead product candidate DUR-928.  DUR-928 is an endogenous, ... broad applicability in metabolic diseases such as nonalcoholic ... and in acute organ injuries such as acute ...
(Date:3/2/2015)... 2015 Click here for additional information on ... DPLO ), the nation,s largest independent specialty pharmacy, ... 31, 2014. All comparisons, unless otherwise noted, are to the ... Fourth Quarter 2014 Highlights include: , Revenue of ... dispensed of 208,000, an increase of 11% , Gross ...
Breaking Medicine Technology:Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 2Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 3Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 4Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 5Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 6Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 7Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 8Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 9Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 10Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 11Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 12Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 13Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 14Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 15DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 2Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 3Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 4Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 5Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 6Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 7Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 8Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 9Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 10Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 11Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 12Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 13Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 14Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 15Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 16Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 17Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 18
... Inc. (OTCQX: DATA), a technology and services company ... trials industry, today announced its participation in the ... will address significant milestones made throughout the pharmaceutical ... technologies are delivering. The EuroMeeting will be held ...
... Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) ... launch of its new formulation of Acetadote ® ... treat acetaminophen poisoning. The proprietary new formulation, which does ... other stabilization or chelating agents, is now stocked at ...
Cached Medicine Technology:DATATRAK to Attend DIA's 23rd Annual EuroMeeting 2New Acetadote® Formulation Now Available in the U.S. 2New Acetadote® Formulation Now Available in the U.S. 3New Acetadote® Formulation Now Available in the U.S. 4
(Date:3/2/2015)... Market Publishers Ltd is extremely happy to ... Industry Analysts Inc and recently added to its catalogue. ... Through 2018, the global radiation therapy equipment market is ... report suggests a holistic analysis of the situation in ... as covers the top market trends. The publication uncovers ...
(Date:3/2/2015)... “ Wants and Needs ” was featured on ... the latest and coolest mobile applications on the iOS, ... expert and host of NewsWatch, conducted the app review ... evaluate priorities. , Whether a person needs help re-orienting ... The app allows people to enter and track wants, ...
(Date:3/2/2015)... Doctors in Novara, Italy have found ... of outcomes for people with mesothelioma than other clinical ... the new study on the Surviving Mesothelioma website. ... Eastern Piedmont followed the cases of 172 mesothelioma ... lung fluid. , “Persistent lung expansion after pleural ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Robins & ... In conjunction with Women in Construction Week (March 1-7, ... or NAWIC) and National Women’s History Month, Robins & ... positively affect the company and the construction industry as ... team, to the dozens of roles in between, each ...
(Date:3/2/2015)... 2015 New York singer/songwriter Richie ... delivering a plenary address entitled Finding the Music ... of Healing and Recovery at this year’s National ... Executive Summit (BHES).     , With more than 300 ... been recorded by some of the biggest names ...
Breaking Medicine News(10 mins):Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 2Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 3Health News:An Application to Evaluate Priorities Was Featured on NewsWatch Television on January 30, 2015 2Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Robins & Morton Recognizes Women In Construction 2Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2
... Day Keeps the Doctor Away - Using QlikView, Inside Info has ... tracking the progression of diseases in the community through more effective ... said Jon Marshall, Managing Director, asteRx. , ... ...
... publisher, Healthcommunities.com, Inc., announces recent additions to urologychannel.com, its urologic ... extensive STD information section, will help people with ... prevent STD complications. , ... Northhampton, ...
... Service Dog Eye Exam event is highly successful in pairing veterinary ophthalmologists ... ... (Vocus) May 20, 2009 -- She has been blind for 13 years. ... ACVO/Merial National Service Dog Eye Exam event , she was elated. ...
... Counter top converts to under counter system. Under counter ionizer converts to counter ... ... health benefits of ionized and alkaline mineral water at home or ... of convertible water ionizers launched by Life Ionizers., , , , ,The company ...
... Wellness Center, one of the nation,s leaders in diagnosing and treating Lyme ... information on the accurate diagnosis and treatment and cure of this highly ... ... The Haverford Wellness Center officially launched a new web site today ...
... Atrophy has just launched a new Medical Advisory Council (MAC). ... most highly respected bodies of SMA medical and clinical experts ... collaborative leadership on issues that improve the quality of medical ... focus on educating families, health care providers, and the public ...
Cached Medicine News:Health News:Innovative Business Intelligence Software Helps Keep Australia Healthy this Winter 2Health News:Innovative Business Intelligence Software Helps Keep Australia Healthy this Winter 3Health News:Valuable New Resources for Treating Sexually Transmitted Disease (STD) 2Health News:Valuable New Resources for Treating Sexually Transmitted Disease (STD) 3Health News:More Than 1,500 Service Dogs Receive Free Sight Saving Eye Exams 2Health News:More Than 1,500 Service Dogs Receive Free Sight Saving Eye Exams 3Health News:More Than 1,500 Service Dogs Receive Free Sight Saving Eye Exams 4Health News:Life Ionizers Promotes Convenience and Healthy Lifestyles With New Convertible Water Ionizers Line 2Health News:Life Ionizers Promotes Convenience and Healthy Lifestyles With New Convertible Water Ionizers Line 3Health News:Haverford Wellness Center Launches Web Site Devoted to Accurate Diagnosis and Proper Treatment to Cure Lyme Disease 2Health News:Haverford Wellness Center Launches Web Site Devoted to Accurate Diagnosis and Proper Treatment to Cure Lyme Disease 3Health News:Families of Spinal Muscular Atrophy Announces its New Medical Advisory Council 2Health News:Families of Spinal Muscular Atrophy Announces its New Medical Advisory Council 3
... X-22 Series is up to 10 inches/ 25 cm ... 11 rotors, the Allegra X-22 Series is the space-saving ... Only 18 inches / 46 cm wide • 11 ... 3 different ways to Spin 1.5 mL & ...
... purpose centrifuges offer high-volume versatility along with ... making them ideal for a wide variety ... Four- or six-place sealed swinging bucket ... rotors offered , Lare capacity (4 x ...
... high performance centrifuge designed to accommodate over ... is refrigerated for heat labile samples. Incorporating ... refrigerated capability with automatic quick cooling from ... 7 min, no maintenance brushless motor, low ...
Inquire...
Medicine Products: